{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:09:58Z","timestamp":1792145398230,"version":"4.4.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejim.2026.106770","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T12:11:25Z","timestamp":1771071085000},"page":"106770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Redefining optimal medical therapy for heart failure in amyloid transthyretin cardiomyopathy"],"prefix":"10.1016","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-9519","authenticated-orcid":false,"given":"Alberto","family":"Aimo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vergaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2026.106770_bib0001","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg","year":"2024","journal-title":"Jama"},{"key":"10.1016\/j.ejim.2026.106770_bib0002","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2026.106770_bib0003","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ejhf.3186","article-title":"Prevalence of wild-type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction: results of the Amylo-VIP-HF study","volume":"26","author":"Tubben","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2026.106770_bib0004","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/eurheartj\/ehaf710","article-title":"Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association","volume":"47","author":"Garcia-Pavia","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2026.106770_bib0005","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2026.106770_bib0006","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac Amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2026.106770_bib0007","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2026.106770_bib0008","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2017.11.037","article-title":"Prevalence of cardiac amyloidosis in patients referred for Transcatheter aortic valve replacement","volume":"71","author":"Scully","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2026.106770_bib0009","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2026.106770_bib0010","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCULATIONAHA.122.062532","article-title":"The future for patients with transthyretin cardiac amyloidosis is looking brighter","volume":"146","author":"Patel","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2026.106770_bib0011","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCHEARTFAILURE.109.910455","article-title":"Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: transthyretin Cardiac Amyloid Study (TRACS)","volume":"4","author":"Bhuiyan","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ejim.2026.106770_bib0012","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jacc.2009.03.073","article-title":"Relationship of venous congestion to worsening renal function","volume":"54","author":"Maqsood","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2026.106770_bib0013","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jacc.2008.08.080","article-title":"Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease","volume":"53","author":"Damman","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2026.106770_bib0014","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2026.106770_bib0015","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1001\/jama.2010.533","article-title":"Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure","volume":"303","author":"Hernandez","year":"2010","journal-title":"Jama"},{"key":"10.1016\/j.ejim.2026.106770_bib0016","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ahj.2014.12.009","article-title":"A reappraisal of loop diuretic choice in heart failure patients","volume":"169","author":"Buggey","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2026.106770_bib0017","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2026.106770_bib0018","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","article-title":"Acetazolamide in acute decompensated heart failure with volume overload","volume":"387","author":"Mullens","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.106770_bib0019","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/eurheartj\/ehac689","article-title":"Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial","volume":"44","author":"Trull\u00e0s","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2026.106770_bib0020","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1038\/s41591-023-02532-z","article-title":"Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial","volume":"29","author":"Ter Maaten","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ejim.2026.106770_bib0021","article-title":"Protocolized natriuresis-guided decongestion improves diuretic response: the multicenter ENACT-HF study","volume":"17","author":"Dauw","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ejim.2026.106770_bib0022","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ahj.2020.12.009","article-title":"Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic","volume":"233","author":"Vaishnav","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2026.106770_bib0023","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0140-6736(11)60101-3","article-title":"Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial","volume":"377","author":"Abraham","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2026.106770_bib0024","article-title":"Safety of midodrine in patients with heart failure with reduced ejection fraction: a retrospective cohort study","volume":"15","author":"Wu","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ejim.2026.106770_bib0025","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/FJC.0000000000001532","article-title":"The impact of midodrine on guideline-directed medical therapy in patients admitted with systolic heart failure","volume":"83","author":"Scoma","year":"2024","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ejim.2026.106770_bib0026","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1177\/2047487320920756","article-title":"Management of complications of cardiac amyloidosis: 10 questions and answers","volume":"28","author":"Aimo","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ejim.2026.106770_bib0027","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/13506129.2021.1966624","article-title":"Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure","volume":"28","author":"Vergaro","year":"2021","journal-title":"Amyloid"},{"key":"10.1016\/j.ejim.2026.106770_bib0028","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jchf.2019.09.011","article-title":"Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction","volume":"8","author":"Serenelli","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejim.2026.106770_bib0029","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2026.106770_bib0030","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jchf.2021.06.007","article-title":"Spironolactone in patients with an echocardiographic HFpEF phenotype suggestive of cardiac amyloidosis: results from TOPCAT","volume":"9","author":"Sperry","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejim.2026.106770_bib0031","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.106770_bib0032","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMra2115011","article-title":"Gliflozins in the management of cardiovascular disease","volume":"386","author":"Braunwald","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.106770_bib0033","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 Inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2026.106770_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101405","article-title":"Sodium-glucose cotransporter 2 inhibitor use and outcomes in transthyretin amyloid cardiomyopathy","volume":"3","author":"Jaiswal","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.ejim.2026.106770_bib0035","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ejhf.3198","article-title":"Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: analyses of short-term efficacy and safety","volume":"26","author":"Lang","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2026.106770_bib0036","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14392","article-title":"Sodium-glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: systematic review and meta-analysis","volume":"55","author":"Karakasis","year":"2025","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ejim.2026.106770_bib0037","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13195966","article-title":"Impact of SGLT2-inhibitor therapy on survival in patients with transthyretin amyloid cardiomyopathy: analysis of a prospective registry study","volume":"13","author":"Schwegel","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejim.2026.106770_bib0038","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.106770_bib0039","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.106770_bib0040","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/ehf2.14621","article-title":"Invasive haemodynamics at rest and exercise in cardiac amyloidosis","volume":"11","author":"Holt","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2026.106770_bib0041","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/ejhf.899","article-title":"Inotropic myocardial reserve deficiency is the predominant feature of exercise haemodynamics in cardiac amyloidosis","volume":"19","author":"Clemmensen","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2026.106770_bib0042","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/13506129.2022.2043270","article-title":"Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"29","author":"Barroso","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.ejim.2026.106770_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.autneu.2019.102590","article-title":"Blood pressure and orthostatic hypotension as measures of autonomic dysfunction in patients from the transthyretin amyloidosis outcomes survey (THAOS)","volume":"222","author":"Gonz\u00e1lez-Duarte","year":"2019","journal-title":"Auton Neurosci"},{"key":"10.1016\/j.ejim.2026.106770_bib0044","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.mayocp.2021.08.006","article-title":"Beta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathy","volume":"97","author":"Barge-Caballero","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejim.2026.106770_bib0045","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/jamacardio.2024.0022","article-title":"Cardiopulmonary exercise testing in evaluating transthyretin amyloidosis","volume":"9","author":"Patel","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejim.2026.106770_bib0046","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022859","article-title":"Lack of association between neurohormonal blockade and survival in transthyretin cardiac amyloidosis","volume":"10","author":"Cheng","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejim.2026.106770_bib0047","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/13506129.2024.2431082","article-title":"Clinical impact of beta-blocker withdrawal in transthyretin amyloid cardiomyopathy","volume":"32","author":"Cabrera-Romero","year":"2025","journal-title":"Amyloid"},{"key":"10.1016\/j.ejim.2026.106770_bib0048","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cardfail.2022.08.008","article-title":"Atrial fibrillation, thromboembolic risk, and anticoagulation in cardiac amyloidosis: a review","volume":"29","author":"Bukhari","year":"2023","journal-title":"J Card Fail"},{"key":"10.1016\/j.ejim.2026.106770_bib0049","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1002\/ejhf.2650","article-title":"Atrial amyloidosis: mechanisms and clinical manifestations","volume":"24","author":"Vergaro","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2026.106770_bib0050","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.repc.2022.12.008","article-title":"Starting sacubitril-valsartan is safe in patients with transthyretin cardiac amyloidosis and impaired ejection fraction","volume":"42","author":"Negreira-Caama\u00f1o","year":"2023","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.ejim.2026.106770_bib0051","article-title":"Cardiac transplantation in transthyretin amyloid cardiomyopathy: outcomes from three decades of tertiary center experience","volume":"9","author":"Razvi","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ejim.2026.106770_bib0052","doi-asserted-by":"crossref","first-page":"e1323","DOI":"10.1097\/TXD.0000000000001323","article-title":"Heart transplantation, either alone or combined with liver and kidney, a viable treatment option for selected patients with severe cardiac amyloidosis","volume":"8","author":"Guendouz","year":"2022","journal-title":"Transplant Direct"},{"key":"10.1016\/j.ejim.2026.106770_bib0053","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14028","article-title":"United network for organ sharing outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis","volume":"34","author":"Griffin","year":"2020","journal-title":"Clin Transplant"},{"key":"10.1016\/j.ejim.2026.106770_bib0054","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007931","article-title":"Durable mechanical circulatory support in patients with amyloid cardiomyopathy: insights from INTERMACS","volume":"13","author":"Michelis","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ejim.2026.106770_bib0055","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.healun.2013.01.987","article-title":"Left ventricular device implantation for advanced cardiac amyloidosis","volume":"32","author":"Swiecicki","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.ejim.2026.106770_bib0056","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13663","article-title":"Mechanical circulatory support for cardiac amyloidosis","volume":"33","author":"Kittleson","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.ejim.2026.106770_bib0057","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.transproceed.2020.08.020","article-title":"Outcomes of heart transplantation in cardiac amyloidosis patients: a single center experience","volume":"53","author":"Chen","year":"2021","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ejim.2026.106770_bib0058","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin Amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.106770_bib0059","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/eurheartj\/ehaf667","article-title":"Transthyretin amyloid cardiomyopathy: from cause to novel treatments","volume":"47","author":"Fontana","year":"2026","journal-title":"Eur Heart J"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526000750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526000750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T04:13:39Z","timestamp":1780287219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620526000750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":59,"alternative-id":["S0953620526000750"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2026.106770","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Redefining optimal medical therapy for heart failure in amyloid transthyretin cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2026.106770","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106770"}}